Analysis of Dermal Fibroblasts and Immune Cells During Systemic Sclerosis (Skin-SSC)

University Hospital, Lille

Status

Enrolling

Conditions

Systemic Sclerosis

Treatments

Other: Blood sampling and skin biopsy

Study type

Observational

Funder types

Other

Identifiers

NCT05273138

2021-A03137-34 (Other Identifier)

2021_0611

Details and patient eligibility

About

The pathophysiology of systemic sclerosis (SSc) is still poorly understood and there are no effective treatments for this disease. SSc is a heterogeneous disease with varying severity. The heterogeneity of fibroblast profiles, observed in other fibrosing pathologies, has never been thoroughly explored in the skin of SSc patients. The immune system, and in particular B lymphocytes, plays a central role in the pathophysiology of SSc. The interactions between B lymphocytes and the cells responsible for excess collagen production, i.e. fibroblasts, are not fully elucidated The main objective is to analyze the heterogeneity of fibroblasts and infiltrating immune cells as well as their molecular signature in the skin of patients with SSc

Enrollment

40 estimated patients

Sex

All

Ages

18+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Man or woman over 18 years of age
With a systemic sclerosis meeting the ACR-EULAR 2013 criteria Having signed an informed consent
Being insured

Exclusion criteria

Syndrome of overlap with another connective tissue disease according to the international diagnostic criteria
Immunosuppressive treatment within 12 months
Dosage of current corticosteroid therapy ≥10mg/d
Protected minors or adults
Pregnant or breastfeeding women
Deprived of their liberty
Persons in emergency situations
Persons who have refused or are unable to give informed consent